Papaevangelou G, Roumeliotou-Karayannis A, Tassopoulos N, Richardson S C, Stathopoulou P, Papadoyannakis N, Tsantoulis N, Politi K, Tassiopoulou A
Eur J Epidemiol. 1985 Jun;1(2):100-3. doi: 10.1007/BF00141800.
The prevalence of serologic evidence of hepatitis B virus infection in various populations in Greece was examined to provide data for formulating cost-effective strategies for prevaccination screening. Markers were detected in 17.5% of 320 healthy persons, 73.3% of 273 multiply transfused patients and 61.0% of 146 haemodialysis patients. In multiply transfused patients, antibody to hepatitis B surface antigen (anti-HBs) was significantly more common than antibody to core antigen (anti-HBc) (67.0%, 44.3%), while the opposite was true for haemodialysis patients (43.8%, 57.5%). These data suggest that it may be most cost-effective to screen only for anti-HBs in multiply transfused patients and only anti-HBc in haemodialysis patients. Vaccination without screening may be more cost-effective for healthy persons. Anti-HBs and anti-HBc were detected with similar frequencies (14.7%, 15.9%), thus neither offers an advantage in screening healthy persons, although use of anti-HBc may facilitate detection of chronic carriers. These data indicate that the choice of marker for pre-vaccination screening should depend on the population under consideration.
对希腊不同人群中乙肝病毒感染血清学证据的流行情况进行了调查，以便为制定具有成本效益的疫苗接种前筛查策略提供数据。在320名健康人中，17.5%检测到相关标志物；在273名多次输血患者中，73.3%检测到相关标志物；在146名血液透析患者中，61.0%检测到相关标志物。在多次输血患者中，乙肝表面抗原抗体（抗-HBs）比核心抗原抗体（抗-HBc）更为常见（分别为67.0%和44.3%），而在血液透析患者中情况则相反（分别为43.8%和57.5%）。这些数据表明，对多次输血患者仅筛查抗-HBs、对血液透析患者仅筛查抗-HBc可能最具成本效益。对健康人而言，不进行筛查直接接种疫苗可能更具成本效益。抗-HBs和抗-HBc的检测频率相似（分别为14.7%和15.9%），因此在筛查健康人时两者都没有优势，不过使用抗-HBc可能有助于检测慢性携带者。这些数据表明，疫苗接种前筛查标志物的选择应取决于所考虑的人群。
